Stockreport
'Two ways of calculating': Trump defends his mathematically impossible calculations on drug prices [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
During a Thursday event announcing a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products , Trump defended his past claims that prices on prescription medications had been cut by well over 100% — something that is mathematically impossible without manufacturers dropping prices to zero and then presumably paying consumers to use their product. Trump acknowledged having boasted that his efforts to lower drug prices had reduced what consumers pay by “500%, 600%.” But he added, “We also sometimes say 50%, 60%” and called it a "different kind of calculation" that could go up to "70, 80 and 90%." “People understand that better,” Trump said. “But they're two ways of calculating” and “either way, it doesn't make any difference.” There could indeed be two ways of calculating such things — but the difference is very important. One is correct. The other is nonmathematical. It was one of several times Trump used his own — but incorrect — math during the drug pri
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. [Yahoo! Finance][Yahoo! Finance]
- FDA approves first gene therapy for genetic hearing loss [MSNBC.com][MSNBC.com]
- Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.[GlobeNewswire]
- Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free [CNBC][CNBC]
- FDA approves first gene therapy for inherited deafness, shown to restore hearing for children with rare condition [CNN][CNN]
- More
REGN
SEC Filings
SEC Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website
- More